Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 41 citing articles:

Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trials
Nhân Thị Hồ, Steven G. Hughes, Van Thanh Ta, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 24
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
Amit Saraf, Rohan Gurjar, Swarnendu Kaviraj, et al.
Nature Medicine (2024) Vol. 30, Iss. 5, pp. 1363-1372
Open Access | Times Cited: 19
Frameworks for transformational breakthroughs in RNA-based medicines
John R. Androsavich
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 6, pp. 421-444
Closed Access | Times Cited: 18
Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 4, pp. 341-343
Open Access | Times Cited: 17
Cost-effectiveness models assessing COVID-19 booster vaccines across eight countries: A review of methods and data inputs
Darvin Scott Smith, Maarten J. Postma, David N. Fisman, et al.
Vaccine (2025) Vol. 51, pp. 126879-126879
Closed Access | Times Cited: 1
Rational formulation and industrial manufacturing of lipid-based complex injectables: Landmarks and trends
Mariana Biscaia-Caleiras, Nuno A. Fonseca, Ana Sofia Lourenço, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 617-639
Closed Access | Times Cited: 13
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Norbert Pardi, Florian Krammer
Nature Reviews Drug Discovery (2024)
Closed Access | Times Cited: 10
Self-Amplifying RNA: A Second Revolution of mRNA Vaccines against COVID-19
Noelia Silva-Pilipich, Uxue Beloki, Laura Salaberry, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 318-318
Open Access | Times Cited: 7
Advances in the design and delivery of RNA vaccines for infectious diseases
Abhijeet Lokras, Thomas Rønnemoes Bobak, Saahil Baghel, et al.
Advanced Drug Delivery Reviews (2024) Vol. 213, pp. 115419-115419
Open Access | Times Cited: 7
Advanced technologies for the development of infectious disease vaccines
Akash Gupta, Arnab Rudra, Kaelan Reed, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 12, pp. 914-938
Closed Access | Times Cited: 7
Trans-Amplifying RNA: A Journey from Alphavirus Research to Future Vaccines
Ayşegül Yıldız, Cristian Răileanu, Tim Beißert
Viruses (2024) Vol. 16, Iss. 4, pp. 503-503
Open Access | Times Cited: 5
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine
Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, et al.
The Lancet Infectious Diseases (2024)
Open Access | Times Cited: 5
Characteristics of humoral responses to the first coronavirus disease booster vaccine and breakthrough infection in central China: a multicentre, prospective, longitudinal cohort study
Junhong Xu, Youhua Yuan, Guohua Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers
Christian J. Maine, Shigeki J. Miyake-Stoner, Darina Spasova, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models
Cheng Chang, Harsh Patel, Annette Ferrari, et al.
Vaccine (2025) Vol. 51, pp. 126883-126883
Closed Access
Transfection via RNA-Based Nanoparticles: Comparing Encapsulation vs Adsorption Approaches of RNA Incorporation
Amy E. Laturski, Maria T. Dulay, Jillian L. Perry, et al.
Bioconjugate Chemistry (2025)
Closed Access
Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19
Durgesh Kumar, Kishor Gaikwad, Rushank Gunnale, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Targeted suppression of type 1 interferon signaling during RNA delivery enhances vaccine-elicited immunity
Byungji Kim, Ryan R. Hosn, Tanaka Remba, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Next-Generation Coronavirus Disease 2019 Vaccines
Kathryn E. Stephenson
Infectious Disease Clinics of North America (2025)
Closed Access
Self-amplifying RNA COVID-19 vaccine
Christopher J. Wayne, Anna K. Blakney
Cell (2024) Vol. 187, Iss. 8, pp. 1822-1822.e1
Closed Access | Times Cited: 4
The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial
Chunhua Zhou, Yuan-zheng Qiu, Jianxin Wang, et al.
Emerging Microbes & Infections (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 3
Single-Dose Immunogenic DNA Vaccines Coding for Live-Attenuated Alpha- and Flaviviruses
Peter Pushko, Igor S. Lukashevich, Dylan M. Johnson, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 428-428
Open Access | Times Cited: 3
Efficient in vitro and in vivo transfection of self-amplifying mRNA with linear poly(propylenimine) and poly(ethylenimine-propylenimine) random copolymers as non-viral carriers
Lisa Opsomer, Somdeb Jana, Ine Mertens, et al.
Journal of Materials Chemistry B (2024) Vol. 12, Iss. 16, pp. 3927-3946
Open Access | Times Cited: 3
The Platform Technology Approach to mRNA Product Development and Regulation
John Howard Skerritt, Carolyn Tucek-Szabo, Brett Sutton, et al.
(2024)
Open Access | Times Cited: 3
The Platform Technology Approach to mRNA Product Development and Regulation
John Howard Skerritt, Carolyn Tucek-Szabo, Brett Sutton, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 528-528
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top